Prenatal exposure to perfluoroalkyl substances modulates neonatal serum phospholipids, increasing risk of type 1 diabetesDivision of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.
Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
School of Science and Technology, Örebro University, Örebro, Sweden.
School of Science and Technology, Örebro University, Örebro, Sweden.
Örebro University, School of Science and Technology.
Immunogenetics Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland; Department of Clinical Microbiology, Turku University Hospital, Turku, Finland.
Public Health Promotion Unit, National Institute for Health and Welfare, Helsinki, Finland; Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Research, Development and Innovation Center, Tampere, Finland; Tampere Center for Child Health Research, Tampere University Hospital, Tampere, Finland.
Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.
Norwegian University of Life Sciences, Oslo, Norway; National Institute of Occupational Health, Oslo, Norway.
Tampere University Hospital, Research, Development and Innovation Center, Tampere, Finland.
Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.
Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Research, Development and Innovation Center, Tampere, Finland; Tampere Center for Child Health Research, Tampere University Hospital, Tampere, Finland.
Show others and affiliations
2020 (English)In: Environment International, ISSN 0160-4120, E-ISSN 1873-6750, Vol. 143, article id 105935Article in journal (Refereed) Published
Abstract [en]
In the last decade, increasing incidence of type 1 diabetes (T1D) stabilized in Finland, a phenomenon that coincides with tighter regulation of perfluoroalkyl substances (PFAS). Here, we quantified PFAS to examine their effects, during pregnancy, on lipid and immune-related markers of T1D risk in children. In a mother-infant cohort (264 dyads), high PFAS exposure during pregnancy associated with decreased cord serum phospholipids and progression to T1D-associated islet autoantibodies in the offspring. This PFAS-lipid association appears exacerbated by increased human leukocyte antigen-conferred risk of T1D in infants. Exposure to a single PFAS compound or a mixture of organic pollutants in non-obese diabetic mice resulted in a lipid profile characterized by a similar decrease in phospholipids, a marked increase of lithocholic acid, and accelerated insulitis. Our findings suggest that PFAS exposure during pregnancy contributes to risk and pathogenesis of T1D in offspring.
Place, publisher, year, edition, pages
Elsevier, 2020. Vol. 143, article id 105935
Keywords [en]
Bile acids, Lipidomics, Mass spectrometry, PFAS, Type 1 diabetes
National Category
Occupational Health and Environmental Health
Identifiers
URN: urn:nbn:se:oru:diva-84459DOI: 10.1016/j.envint.2020.105935ISI: 000602318000009PubMedID: 32634666Scopus ID: 2-s2.0-85087364238OAI: oai:DiVA.org:oru-84459DiVA, id: diva2:1452903
Funder
Swedish Research Council, 2016-05176Swedish Research Council Formas, 2019-00869Academy of Finland, 292568Novo Nordisk, NNF190C0057418Knowledge Foundation
Note
Funding Agencies:
United States Department of Health & Human Services
National Institutes of Health (NIH) - USA
NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)1DP3DK094338-01
Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research 250114
Academy of Finland postdoctoral grant 323171
Medical Research Funds, Tampere University Hospital
Juvenile Diabetes Research Foundation 2-SRA-2016-341-S-B 2-SRA-2016-289-S-B
Medical Research Funds, Helsinki University Hospital
2020-07-082020-07-082021-01-25Bibliographically approved